Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report). The ...

Cartesian Therapeutics Inc. unveiled 12-month efficacy and safety data from the phase IIb trial of Descartes-08 in participants with generalized myasthenia gravis (MG). Participants dosed with a ...

The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.

Analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Allogene Therapeutics in a research note issued to ...

Allogene Therapeutics (ALLO) announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast ...

Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for Allogene Therapeutics in a ...

And allogeneic cell therapy leader Allogene Therapeutics also lost about 6% in market value. After the initial shock, industry watchers were left parsing through the implications for biopharma ...

In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that outperformed broader market last week. Wall Street’s main indices ...

The company share took a dive after the company informed, through an exchange filing, that Lyndra Therapeutics Inc, a company that Sun Pharma has stakes in, had ceased operations. Read Also Roshni ...

RNA therapeutics have existed since the late 90s but have only come into focus in the last few years. This renewed interest has largely been attributed to the success of messenger RNA (mRNA) vaccines ...